Hillstream BioPharma, Inc.
HILSNASDAQHealthcare
$0.24
+$0.01(+5.66%)
Market Cap$4171840
P/E Ratio—
52W High$2.65
52W Low$0.1723
Hillstream BioPharma, Inc. (HILS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
HILS · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 13, 2023EPS Actual
-$0.11
Est. -$0.05 · -110.5%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 13, 2023
After Market Close
▼ Miss EPS
HILS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2023 | Nov 13, 2023 | -$0.05 | -$0.11 | -110.5% | — | — | — |
| — Q3 FY2023 | Aug 11, 2023 | $0.16 | $0.16 | +0.0% | — | — | — |
| ▲ Q2 FY2023 | May 22, 2023 | $0.11 | $0.23 | +109.1% | — | — | — |
| — Q1 FY2023 | Mar 16, 2023 | — | $0.15 | — | — | — | — |
| — Q4 FY2022 | Nov 14, 2022 | — | $0.18 | — | — | — | — |
| — Q3 FY2022 | Aug 10, 2022 | — | -$0.14 | — | — | — | — |
| — Q2 FY2022 | May 13, 2022 | — | -$0.28 | — | — | — | — |
| — Q4 FY2021 | Dec 31, 2021 | — | $0.24 | — | — | — | — |
Q4 FY2023
Nov 13, 2023Miss
EPS Actual
-$0.11
EPS Est.
-$0.05
EPS Surpr.
-110.5%
Revenue
—
Q3 FY2023
Aug 11, 2023
EPS Actual
$0.16
EPS Est.
$0.16
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2023
May 22, 2023Beat
EPS Actual
$0.23
EPS Est.
$0.11
EPS Surpr.
+109.1%
Revenue
—
Q1 FY2023
Mar 16, 2023
EPS Actual
$0.15
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Nov 14, 2022
EPS Actual
$0.18
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Aug 10, 2022
EPS Actual
-$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2022
May 13, 2022
EPS Actual
-$0.28
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2021
Dec 31, 2021
EPS Actual
$0.24
EPS Est.
—
EPS Surpr.
—
Revenue
—
No analyst estimates available for HILS.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2023 | Nov 13, 2023 | -110.5% | $0.18 | — | — |
| ▲ Q3 FY2023 | Aug 11, 2023 | +0.0% | $0.31 | $0.32 | +1.93% |
| ▲ Q2 FY2023 | May 22, 2023 | +109.1% | $0.37 | $0.39 | +4.32% |
| — Q1 FY2023 | Mar 16, 2023 | — | $0.98 | $0.98 | +0.31% |
| — Q4 FY2022 | Nov 14, 2022 | — | $0.47 | $0.47 | +0.64% |
| — Q3 FY2022 | Aug 10, 2022 | — | $1.26 | $1.21 | -3.97% |
| — Q2 FY2022 | May 13, 2022 | — | $0.96 | $0.97 | +0.93% |
| — Q4 FY2021 | Dec 31, 2021 | — | No price data | $3.48 | — |
Q4 FY2023—
Report Date
Nov 13, 2023
EPS Beat/Miss
-110.5%
Price Before
$0.18
Price After
—
Q3 FY2023+1.93%
Report Date
Aug 11, 2023
EPS Beat/Miss
+0.0%
Price Before
$0.31
Price After
$0.32
Q2 FY2023+4.32%
Report Date
May 22, 2023
EPS Beat/Miss
+109.1%
Price Before
$0.37
Price After
$0.39
Q1 FY2023+0.31%
Report Date
Mar 16, 2023
EPS Beat/Miss
—
Price Before
$0.98
Price After
$0.98
Q4 FY2022+0.64%
Report Date
Nov 14, 2022
EPS Beat/Miss
—
Price Before
$0.47
Price After
$0.47
Q3 FY2022-3.97%
Report Date
Aug 10, 2022
EPS Beat/Miss
—
Price Before
$1.26
Price After
$1.21
Q2 FY2022+0.93%
Report Date
May 13, 2022
EPS Beat/Miss
—
Price Before
$0.96
Price After
$0.97
Q4 FY2021—
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
—
Price After
$3.48
Avg Beat Reaction+3.13%
Beat Rate2 / 8 quarters
Largest Move+4.32% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: HILS ends December
Hillstream BioPharma, Inc. (HILS) most recently reported earnings on November 13, 2023 for Q4 FY2023, posting EPS of $-0.11 — missing the analyst consensus of $-0.05 by -110.5%. The next HILS earnings date is expected around September 1, 2026.
Each quarter, investors track HILS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. HILS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
HILS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
HILS earnings · 5 questionsHillstream BioPharma, Inc.'s next earnings report is expected around September 1, 2026. HILS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; HILS historically reports after market close (AMC).
HILS earnings datewhen is HILS earningsHILS next earnings datewhen does HILS report earningsHILS earnings calendar
▸ Source: FMP · Hillstream BioPharma, Inc. SEC filings · US GAAP · Hillstream BioPharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026